• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.一名接受维莫非尼和考比替尼治疗的转移性黑色素瘤患者发生急性多发性神经病。
Neurol Clin Pract. 2017 Oct;7(5):418-420. doi: 10.1212/CPJ.0000000000000331.
2
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.达拉非尼联合曲美替尼与维莫非尼联合考比替尼用于既往未治疗的转移性黑色素瘤患者的间接治疗比较
J Hematol Oncol. 2017 Jan 4;10(1):3. doi: 10.1186/s13045-016-0369-8.
3
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.接受维莫非尼±考比替尼治疗的 BRAF 突变阳性转移性黑色素瘤患者中，与酸还原剂同时给药和维莫非尼剂量对生存的影响。
Eur J Cancer. 2019 Jul;116:45-55. doi: 10.1016/j.ejca.2019.05.002. Epub 2019 Jun 4.
4
Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.考比替尼联合维莫非尼：BRAF（V600）突变阳性不可切除或转移性黑色素瘤的综述
Drugs. 2016 Apr;76(5):605-15. doi: 10.1007/s40265-016-0562-7.
5
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.BRAF V600 突变型转移性黑色素瘤生存和治疗结局的建模预后亚组：4 项随机临床试验的汇总分析。
JAMA Oncol. 2018 Oct 1;4(10):1382-1388. doi: 10.1001/jamaoncol.2018.2668.
6
Cobimetinib.考比替尼
Ann Pharmacother. 2017 Feb;51(2):146-153. doi: 10.1177/1060028016672037. Epub 2016 Oct 4.
7
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.考比替尼联合维莫非尼治疗晚期 BRAF(V600)突变型黑色素瘤（coBRIM）：一项随机、双盲、III 期临床试验的更新疗效结果。
Lancet Oncol. 2016 Sep;17(9):1248-60. doi: 10.1016/S1470-2045(16)30122-X. Epub 2016 Jul 30.
8
Cardiac toxicity of combined vemurafenib and cobimetinib administration
.维莫非尼与考比替尼联合给药的心脏毒性
Int J Clin Pharmacol Ther. 2019 May;57(5):259-263. doi: 10.5414/CP203379.
9
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.阿替利珠单抗、维莫非尼和考比替尼作为不可切除的晚期 BRAF 突变阳性黑色素瘤的一线治疗药物（IMspire150）：随机、双盲、安慰剂对照、III 期临床试验的主要分析。
Lancet. 2020 Jun 13;395(10240):1835-1844. doi: 10.1016/S0140-6736(20)30934-X.
10
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.联合维莫非尼和考比替尼治疗 BRAF 突变型黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.

引用本文的文献

1
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System.转移性结直肠癌中口服酪氨酸激酶抑制剂引起的神经精神药物不良反应：来自美国食品药品监督管理局不良事件报告系统的分析
Front Oncol. 2023 Oct 31;13:1268672. doi: 10.3389/fonc.2023.1268672. eCollection 2023.
2
BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma.BRAF 抑制剂治疗相关脑炎在转移性黑色素瘤患者中的应用。
Oncologist. 2021 Oct;26(10):e1887-e1889. doi: 10.1002/onco.13896. Epub 2021 Jul 17.
3
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature.癌症患者靶向治疗后的神经肌肉并发症：超越免疫检查点抑制剂。病例报告及文献综述。
Neurol Sci. 2021 Apr;42(4):1405-1409. doi: 10.1007/s10072-020-04604-1. Epub 2020 Aug 11.
4
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation.BRAF+MEK抑制剂联合用药的安全性：严重不良事件评估。
Cancers (Basel). 2020 Jun 22;12(6):1650. doi: 10.3390/cancers12061650.
5
Neurologic complications of immune checkpoint inhibitors.免疫检查点抑制剂的神经系统并发症。
Expert Opin Drug Saf. 2020 Apr;19(4):479-488. doi: 10.1080/14740338.2020.1738382. Epub 2020 Mar 11.

本文引用的文献

1
Vemurafenib-induced bilateral facial palsy.维莫非尼诱发的双侧面神经麻痹。
J Postgrad Med. 2014 Apr-Jun;60(2):187-8. doi: 10.4103/0022-3859.132339.
2
Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.抗 PD-1 治疗后应用 vemurafenib 时黑色素瘤患者出现严重皮肤和神经毒性。
Cancer Immunol Res. 2013 Dec;1(6):373-7. doi: 10.1158/2326-6066.CIR-13-0092.
3
Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.在转移性黑色素瘤患者中，面部麻痹作为维莫非尼治疗的一种副作用。
J Clin Oncol. 2013 Apr 20;31(12):e215-7. doi: 10.1200/JCO.2012.45.7028. Epub 2013 Mar 18.
4
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.BRAF 抑制与转移性黑色素瘤患者中黑色素瘤相关抗原表达增强和更有利的肿瘤微环境相关。
Clin Cancer Res. 2013 Mar 1;19(5):1225-31. doi: 10.1158/1078-0432.CCR-12-1630. Epub 2013 Jan 10.
5
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.维莫非尼治疗 BRAF V600 突变型晚期黑色素瘤的生存情况。
N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.
6
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data.吉兰-巴雷综合征和费舍尔综合征：免疫接种安全性数据收集、分析及呈现的病例定义与指南
Vaccine. 2011 Jan 10;29(3):599-612. doi: 10.1016/j.vaccine.2010.06.003. Epub 2010 Jun 18.
7
Gangliosides of human melanoma.人类黑色素瘤的神经节苷脂
Cancer. 1989 Mar 15;63(6):1166-74. doi: 10.1002/1097-0142(19890315)63:6<1166::aid-cncr2820630621>3.0.co;2-5.

Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.

作者信息

Compter Annette, Boogerd Willem, van Thienen Johannes V, Brandsma Dieta

机构信息

Departments of Neuro-Oncology (AC, WB, DB) and Medical Oncology (JVvT), Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam; and Department of Neurology and Neurosurgery (AC), University Medical Center Utrecht, the Netherlands.

出版信息

Neurol Clin Pract. 2017 Oct;7(5):418-420. doi: 10.1212/CPJ.0000000000000331.

DOI:10.1212/CPJ.0000000000000331
PMID:29620078
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5874462/
Abstract
摘要